PERIGEE HEALTH - a Market Access Agency | Seasoned Biotech/Healthcare Executive | Market Access Executive | Early Seed & Capital Funding Experience | Board Member
An old one but a good one nonetheless. Successfully launching a rare disease drug in a patient-centric world requires a true commitment to understanding and engaging with the rare disease community in order to foster innovative methods for patient identification, strategically navigating patient access, and provide comprehensive support for patients and caregivers throughout their treatment journey. The core focuses of pharmaceutical companies haven't changed much, though I'd say that thanks to a rise in AI/ML, there has been an increase in the prominence and utilization of real-world data and evidence. Because the underlying drivers and pillars are still largely the same as they were a few years ago, we're likely going to see a complete shift in patient experience, driven by advancements in treatment accessibility, engagement, and real-world evidence generation, ultimately reshaping the landscape of rare disease therapeutics. #RareDiseases #DrugDevelopment #PatientCare #Healthcare
